147 related articles for article (PubMed ID: 3466728)
1. Correlation of surface marker expression with morphologically and immunologically defined subclasses of acute myeloid leukaemias.
Drexler HG; Menon M; Klein M; Bhoopalam N; Messmore HL; Minowada J
Clin Exp Immunol; 1986 Aug; 65(2):363-72. PubMed ID: 3466728
[TBL] [Abstract][Full Text] [Related]
2. Reactivity patterns of monoclonal antibodies positive on myelomonocytic leukemia cells as defined by esterase isoenzyme analysis.
Drexler HG; Menon M; Gaedicke G; Minowada J
Cancer Immunol Immunother; 1986; 21(3):188-92. PubMed ID: 3457629
[TBL] [Abstract][Full Text] [Related]
3. Antigenic phenotype of the myeloid leukaemic cells defined by monoclonal antibodies.
Robak T; Korycka A
Arch Immunol Ther Exp (Warsz); 1987; 35(1):33-42. PubMed ID: 3477133
[TBL] [Abstract][Full Text] [Related]
4. Use of surface marker analysis to predict outcome of adult acute myeloblastic leukemia.
Griffin JD; Davis R; Nelson DA; Davey FR; Mayer RJ; Schiffer C; McIntyre OR; Bloomfield CD
Blood; 1986 Dec; 68(6):1232-41. PubMed ID: 2946331
[TBL] [Abstract][Full Text] [Related]
5. Reactivity pattern of 'myeloid monoclonal antibodies' with emphasis on MCS-2.
Drexler HG; Sagawa K; Menon M; Minowada J
Leuk Res; 1986; 10(1):17-23. PubMed ID: 3456072
[TBL] [Abstract][Full Text] [Related]
6. Modulation of cell surface antigens induced by 12-O-tetradecanoyl-phorbol 13-acetate in two myeloblastic cell lines, a promyelocytic cell line, and a monoblastic cell line: detection with five monoclonal antibodies.
Sugimoto T; Tatsumi E; Takeda K; Minato K; Sagawa K; Minowada J
J Natl Cancer Inst; 1984 Apr; 72(4):923-8. PubMed ID: 6368942
[TBL] [Abstract][Full Text] [Related]
7. Differentiation phenotypes on cells of acute myeloid leukemia studied by My7, My9, My4, Mo1 and Ja monoclonal antibodies.
Büchi G; Girotto M; Baldini G; Grosso E; Termine G; Gario S; Autino R; Zappalà C; Ganio D
Pathologica; 1987; 79(1064):699-704. PubMed ID: 3503228
[No Abstract] [Full Text] [Related]
8. Surface marker analysis in acute myeloid leukaemia and correlation with FAB classification.
San Miguel JF; Gonzalez M; Cañizo MC; Anta JP; Zola H; Lopez Borrasca A
Br J Haematol; 1986 Nov; 64(3):547-60. PubMed ID: 3466644
[TBL] [Abstract][Full Text] [Related]
9. CD117 (c-kit) is a restricted antigen of acute myeloid leukemia and characterizes early differentiative levels of M5 FAB subtype.
Cascavilla N; Musto P; D'Arena G; Melillo L; Carella AM; Petrilli MP; Sanpaolo G; Carotenuto M
Haematologica; 1998 May; 83(5):392-7. PubMed ID: 9658721
[TBL] [Abstract][Full Text] [Related]
10. Leukemia-associated marker combinations in acute leukemia suitable for detection of minimal residual disease.
Babusíková O; Mesárosová A; Koníková M; Kusenda J; Glasová M; Klobusická M
Neoplasma; 1993; 40(5):275-81. PubMed ID: 8272155
[TBL] [Abstract][Full Text] [Related]
11. Staging of leukemic progenitor cells in acute myeloid leukemia by phenotyping with myeloid monoclonal antibodies.
Hast R; Dowding C; Robak T; Goldman JM
Exp Hematol; 1986 Nov; 14(10):981-7. PubMed ID: 3464449
[TBL] [Abstract][Full Text] [Related]
12. Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies.
Graf M; Hecht K; Reif S; Pelka-Fleischer R; Pfister K; Schmetzer H
Eur J Haematol; 2004 Feb; 72(2):89-106. PubMed ID: 14962246
[TBL] [Abstract][Full Text] [Related]
13. Application of series of monoclonal antibodies against human white cell differentiation antigens and the common ALL antigen in the characterization of leukemia cells.
Hołowiecki J; Stella-Hołowiecka B; Krawczyk-Kuliś M; Wiechnik E; Japa J; Jarczok K; Rudzka E; Duraj M
Arch Immunol Ther Exp (Warsz); 1984; 32(1):43-9. PubMed ID: 6433853
[TBL] [Abstract][Full Text] [Related]
14. Classification of acute myeloid leukemias--a comparison of FAB and immunophenotyping.
Drexler HG
Leukemia; 1987 Oct; 1(10):697-705. PubMed ID: 3312833
[TBL] [Abstract][Full Text] [Related]
15. Expression of monocytic and T-lymphocytic phenotype in a variant form of acute promyelocytic leukaemia (M3).
Sato T; Abe R; Kawaguchi M; Uchida T; Kariyone S
Scand J Haematol; 1986 Aug; 37(2):151-3. PubMed ID: 3489982
[TBL] [Abstract][Full Text] [Related]
16. Immunophenotyping of acute myeloid leukemia using monoclonal antibodies and the alkaline phosphatase-antialkaline phosphatase technique.
Hanson CA; Gajl-Peczalska KJ; Parkin JL; Brunning RD
Blood; 1987 Jul; 70(1):83-9. PubMed ID: 3297208
[TBL] [Abstract][Full Text] [Related]
17. Contrasting antigenic maturation patterns in M0-M2 versus M3 acute myeloid leukemias.
Lewis RE; Cruse JM; Webb RN; Sanders CM; Beason K
Exp Mol Pathol; 2007 Oct; 83(2):269-73. PubMed ID: 17603036
[TBL] [Abstract][Full Text] [Related]
18. High expression of urokinase plasminogen activator receptor (UPA-R) in acute myeloid leukemia (AML) is associated with worse prognosis.
Graf M; Reif S; Hecht K; Pelka-Fleischer R; Pfister K; Schmetzer H
Am J Hematol; 2005 May; 79(1):26-35. PubMed ID: 15849776
[TBL] [Abstract][Full Text] [Related]
19. Single cell studies on the immunological marker profile of plasmacytoid T-zone cells.
Beiske K; Munthe-Kaas A; Davies CD; Marton PF; Godal T
Lab Invest; 1987 Apr; 56(4):381-93. PubMed ID: 3104684
[TBL] [Abstract][Full Text] [Related]
20. Diversity of acute non-lymphocytic leukemia analyzed with monoclonal antibodies reactive with myeloid differentiation antigens.
Morishima Y; Morishita Y; Okumura M; Minami S; Ohno R
Jpn J Clin Oncol; 1986 Mar; 16(1):49-57. PubMed ID: 3702071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
